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yes. The use of low-dose aspirin 
during pregnancy decreases the risk of 
preeclampsia for women considered at 
increased risk. The effect is smaller for 
women without risk factors (strength of 
recommendation [sor]: a, based on 
randomized controlled trials [rCTs] and 
systematic reviews [srs] of rCTs). 
 rates of preterm delivery, perinatal 
death, and incidence of small-for-
gestational age infants are decreased for 
women treated with low-dose aspirin (sor: 
a, based on srs and rCTs). a meta-
analysis of rCTs has found no increased 
rates of harm from low-dose aspirin 
therapy, including placental abruption or 
other antepartum bleeding complications 
(sor: a, based on srs and rCTs). 
i prescribe 81 mg/day of aspirin for women 
with previous severe preeclampsia 
Confused about when to use aspirin in 
pregnancy? you’re not alone. over my 
20 years of practice, I have reacted to 
disparate guidelines ranging from “never 
use aspirin in pregnancy” to “always 
use low-dose aspirin.” This review helps 
simplify my clinical practice. 
With the benefit of evidence from 
multiple rCTs over the past 7 years, 
I now personally use 81 mg of aspirin 
each day in 2 groups of women: those 
who had severe preeclampsia in a prior 
pregnancy, and those who develop signs 
of preeclampsia or strong risk factors for 
it before the third trimester in their current 
pregnancy. 
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z	Evidence	summary
Systematic	reviews	show	aspirin	
lowers	rates	of	preeclampsia
Four SRs published between 2001 and 
20071–4 and a Cochrane Review up-
dated in 20065 have demonstrated that 
low-dose aspirin helps to prevent pre-
eclampsia, reduction in preterm delivery 
rates, and decreased perinatal mortality.
The 2001 Sr by Duley1 included 39 
trials and 30,563 patients. Patients were 
classified either as high-risk (previous se-
vere preeclampsia, diabetes, chronic hy-
pertension, renal disease, or autoimmune 
disease) or moderate-risk (remainder of 
subjects). Four individual studies (with a 
combined weight of 27%) did not sup-
port aspirin therapy. The largest trial 
not supporting aspirin therapy included 
6275 subjects and had a relative risk of 
1.14 (95% CI, 0.94–1.38). 
Most studies in this review compared 
evidence-based answer
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aspirin alone with placebo (28,802 sub-
jects). However, 4 studies either com-
pared combination therapy with aspirin 
or other thromboprophylaxis therapy 
(dipyridamole, heparin, or ozagrel). Al-
though there were differences in risk 
stratification, variable doses of aspirin, 
and varied gestational age at trial entry, 
all studies reported an overall 15% re-
duction of preeclampsia (RR=0.85; 95% 
CI, 0.78–0.92).
The 2003 Sr by coomarasamy2 in-
cluded 14 trials and 12,416 patients. 
The study exclusively evaluated high-
risk pregnancies:  women with history 
(or family history) of preeclampsia, 
chronic hypertension, gestational diabe-
tes, or renal disease. The overall reduc-
tion in preeclampsia was 14% (relative 
risk [RR]=0.86; 95% confidence interval 
[CI], 0.76–0.96). Results were consistent 
across RCTs, and only 2 of the 14 studies 
(with a combined weight of 7.1%) did 
not support aspirin therapy.
ruano’s 2005 Sr3 included 22 tri-
als with 33,598 subjects and specifically 
compared low-risk vs high-risk patients. 
The authors concluded that there was no 
significant reduction in preeclampsia with 
the use of low-dose aspirin in the low-risk 
arm (RR=0.95; 95% CI, 0.81–1.11), and 
a 13% reduction among high-risk sub-
jects (RR=0.87; 95% CI, 0.79–0.96).3 
a 2007 meta-analysis by askie4 in-
cluded 31 trials with 32,217 women and 
their 32,819 infants. Main outcomes (re-
gardless of initial maternal risks) were 1) 
onset of preeclampsia, 2) neonatal death, 
3) preterm birth at <34 weeks gestation, 
4) infant small for gestational age, and 5) 
pregnancy with serious adverse outcome. 
Results of these outcome measures con-
sistently showed a relative risk reduction 
of 10% for subjects taking low-dose as-
pirin, except for neonatal deaths, which 
had a 9% reduction. This study also 
suggested that multiparous women and 
women with a history of hypertensive 
disorder of pregnancy may derive a larg-
er benefit from low-dose aspirin.
a cochrane review5 updated in 2007 
demonstrated that low-dose aspirin pro-
Low-dose	aspirin	reduces	risk	of	preeclampsia,		
but	how	does	it	affect	other	maternal	and	fetal	outcomes?
STuDy  DeveloPmenT of PreTerm neonaTal SGa or low  riSk of abruPTion 
(year)  PreeclamPSia Delivery DeaTh  birTh weiGhT & bleeDinG 
Duley (2001)1 Moderate-risk patients:  8% reduction 14% reduction 8% reduction* not reported 
 15% reduction  nnT=72 nnT= 250
 High-risk patients: 15% reduction  
 nnT=100 
coomarasamy  14% reduction 14% reduction 21% reduction 215-g weight gain  no significant clinical  
(2003)2    in aspirin group difference in risk  
     (rr=0.98)
ruano (2005)3 Low-risk patients:     not reported 
 no significant reduction
 High-risk patients: 13% reduction    
askie (2007)4 10% reduction 10% reduction 9% reduction 10% reduction no significant clinical  
     difference in risk 
     (rr=0.90–1.15)
cochrane  19% reduction 7% reduction 16% reduction 8% reduction* no significant clinical 
(2007)5 nnT=69 (overall), 118 (moderate  nnT=83 nnT=227  difference in risk  
 risk), 18 (high-risk)    (rr=1.06)
* Borderline for statistical significance (rr=0.92). 
sGa, small for gestational age; nnT, number needed to treat; rr, relative risk.
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vided a moderate (19%) reduction in the 
overall risk of developing preeclampsia. 
New stratified analysis of the data in-
dicates that in moderate-risk women, 
antiplatelet therapy is associated with 
a 15% reduction, and that high-risk 
women have a 27% reduction in the 
risk of developing preeclampsia. The ef-
fect on small-for-gestational-age infants 
revealed no overall clinically significant 
differences.
Aspirin	dosing:	One	study		
recommends	>75	mg/day
Studies varied in the aspirin dosage they 
used and duration of treatment. In all 
RCTs, the dose of aspirin ranged from 50 
mg/day to 150 mg/day. Earlier trials used 
lower doses of aspirin (50–75 mg/day), 
while recent trials used 100 mg or more 
per day. 
Early RCTs revealed no correlation 
between the dose of aspirin and the pre-
vention of preeclampsia. However, Vil-
lar et al6 showed a greater effect among 
women treated with doses greater than 
75 mg/day of aspirin (RR=0.49; 95% CI, 
0.38–0.63).6
No	evidence	of	harm		
from	aspirin
There is no evidence of harm from low-
dose aspirin therapy—including placen-
tal abruption, antenatal admissions, fetal 
intraventricular hemorrhage and other 
neonatal bleeding complications, admis-
sion to neonatal care unit, induction of 
labor, or caesarean delivery—regardless 
of initial risk stratification.7 
Recommendations	from	others
The 2002 American College of Obstetri-
cians and Gynecologists Practice Bulletin 
states that low-dose aspirin in women at 
low risk has not been shown to prevent 
preeclampsia and therefore is not recom-
mended. They make no specific statement 
regarding the use of low-dose aspirin in 
moderate- to high-risk pregnancies.8 
The Australasian Society for the 
Study of Hypertension in Pregnancy 
conclude that low-dose aspirin for pre-
vention of preeclampsia is reasonable for 
the following conditions: 1) prior fetal 
loss after first trimester due to placental 
insufficiency or severe fetal growth retar-
dation, and 2) women with severe early 
onset preeclampsia in previous pregnan-
cy necessitating delivery ≤32 weeks ges-
tation. Despite difficulties in predicting 
who will deliver preterm, consider wom-
en who have had severe early-onset pre-
eclampsia in a previous pregnancy for 
low-dose aspirin therapy.9 
The Canadian Hypertension Soci-
ety Consensus Panel concludes low-dose 
aspirin therapy is effective in decreasing 
the incidence of preterm delivery and 
early-onset preeclampsia among women 
at risk of developing the syndrome.10  n
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Multiparous  
women and women  
with a history  
of hypertensive  
disorder of  
pregnancy may 
derive a larger  
benefit from  
low-dose aspirin
